DOI: 10.36347/sjams.2015.v03i01.062

Pages: 310-317

Chronic obstructive pulmonary disease (COPD), caused by chronic inflammation and destruction of the airways and lung parenchyma is usually associated with tobacco smoking or prolonged exposure to other noxious particles and gases. It is a major health problem characterized by progressive airflow obstruction that is sometimes partially reversible. Methylxanthines like theophylline have been used in combination for bronchodilation in COPD since many years. Doxofylline, a novel methylxanthine is claimed to be therapeutically similar but with better safety. This study was designed to compare the efficacy and safety of theophylline and etophylline fixed dose combination with doxofylline at doses commonly used in patients with stable COPD. The study was conducted in the department of Pulmonology. 204 patients were divided into two groups and randomly assigned to a 21 day oral treatment. Group I was administered theophylline 69 mg + etofylline 231mg (Deriphylline Retard 300 mg) once a day and group II was administered doxofylline 400 mg twice a day. Efficacy was measured objectively using spirometric parameters like FEV1 (Forced expiratory volume at the end of 1 second), FVC (Forced vital capacity) and % FEV. Adverse effects were subjectively recorded weekly. Statistical analysis showed no significant difference with respect to spirometric variables and symptom score in the two groups. But significant difference with respect to side effects was observed. Palpitation was the most common adverse effect followed by tremor, insomnia and dyspepsia. CONCLUSION: Though doxofylline has better safety profile, it has no advantage over theophylline and etofylline in terms of efficacy.